Analytical Data
-
Gene name
PSG9
- Application
-
Species
Human
-
Source
HEK293
-
Tag
C-6*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAH20759.1
-
Expression Region
E35-S426
-
AA Sequence
EVTIEAQPPKVSEGKDVLLLVHNLPQNLPGYFWYKGEMTDLYHYIISYIVDGKIIIYGPAYSGRETVYSNASLLIQNVTRKDAGTYTLHIIKRGDETREEIRHFTFTLYLETPKPYISSSNLNPREAMEAVRLICDPETLDASYLWWMNGQSLPVTHRLQLSKTNRTLYLFGVTKYIAGPYECEIRNPVSASRSDPVTLNLLPKLPIPYITINNLNPRENKDVLAFTCEPKSENYTYIWWLNGQSLPVSPGVKRPIENRILILPSVTRNETGPYQCEIQDRYGGLRSNPVILNVLYGPDLPRIYPSFTYYRSGENLDLSCFTESNPPAEYFWTINGKFQQSGQKLFIPQITRNHSGLYACSVHNSATGKEISKSMTVKVSGPCHGDLTESQS
-
Protein Length
Partial
-
Molecular Weight
65.0 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSG9, or Pregnancy-Specific Glycoprotein 9, is a member of the pregnancy-specific glycoprotein family, which has garnered significant interest in reproductive biology and immunology. Discovered initially in the context of human placental tissues, PSG9 plays a crucial role in modulating maternal immune response during pregnancy, thereby allowing for successful fetal development. Its potential influence on both the maternal-fetal interface and immune tolerance has prompted researchers to investigate its implications in various conditions such as preeclampsia, recurrent miscarriage, and even certain cancers. The unique expression patterns of PSG9 during different stages of pregnancy and its involvement in local and systemic immune responses make it a promising target for therapeutic interventions. Advances in recombinant protein technology have enabled the production of PSG9 in heterologous systems, allowing scientists to study its biological activity and protein interactions in detail. By elucidating the functional roles of PSG9 and its molecular pathways, researchers aim to better understand its contributions to reproductive health and its potential implications for managing pregnancy-related complications. The ongoing exploration of PSG9 not only enhances our knowledge of human reproduction but also opens avenues for innovative diagnostic and therapeutic strategies in obstetrics and gynecology.
